1502655-48-2

Basic information

• Product Name: Ledipasvir diacetone
• Synonyms: Ledipasvir diacetone
• CAS NO: 1502655-48-2
• Molecular Formula: C55H66F2N8O8
• Molecular Weight: 1005.1581464
• Mol File: 1502655-48-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ledipasvir diacetone(CAS DataBase Reference)
• NIST Chemistry Reference: Ledipasvir diacetone(1502655-48-2)
• EPA Substance Registry System: Ledipasvir diacetone(1502655-48-2)

Safety Data

• Hazardous Substances Data: 1502655-48-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ledipasvir diacetone is used as an antiviral agent for the treatment of chronic hepatitis C virus (HCV) infections. It targets the NS5A protein, inhibiting the replication of the virus and reducing the viral load in the body.
Used in Combination Therapy:
Ledipasvir diacetone is often used in combination with other antiviral medications to enhance its effectiveness in treating HCV infections. This combined approach helps to achieve higher rates of sustained virologic response and improved liver function in patients with chronic HCV infections.
Clinical Applications:
In clinical trials, Ledipasvir diacetone has demonstrated promising results, showing high rates of sustained virologic response and improved liver function in patients with chronic HCV infections. Its use in combination with other antiviral medications has further increased its therapeutic potential, making it a valuable component in the treatment of hepatitis C.

Upstream product

• 1499193-67-7 C₃₅H₃₂F₂N₆*4ClH 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 67-64-1 acetone 
• 1499193-65-5 (1R,3S,4S)-tert-butyl 3-(6-(7-(2-((S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptan-6-yl)-1H-imidazol-5-yl)-9,9-difluoro-9H-fluoren-2-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 

Downstream Products

• 1502654-87-6 (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)carbamicacid methyl ester D-tartrate salt 
• 1256388-51-8 methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]-hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 

Relevant articles and documents

SOLID FORMS OF AN ANTIVIRAL COMPOUND

Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.

SYNTHESIS OF ANTIVIRAL COMPOUND

The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.